PRODUCT INFORMATION

2 $\mathbf{FORTAZ}^{\mathbb{R}}$

3 (ceftazidime for injection)

4

1

5 $\mathbf{FORTAZ}^{\mathbb{R}}$

6 (ceftazidime sodium injection)

7

8 For Intravenous or Intramuscular Use

10 **DESCRIPTION:** Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for


11 parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-

12 carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-

13 en-3-yl]methyl]-, hydroxide, inner salt, $[6R-[6\alpha,7\beta(Z)]]$. It has the following structure:

14

9



15 16

17 The empirical formula is $C_{22}H_{32}N_6O_{12}S_2$, representing a molecular weight of 636.6.

18 FORTAZ is a sterile, dry-powdered mixture of ceftazidime pentahydrate and sodium carbonate.

19 The sodium carbonate at a concentration of 118 mg/g of ceftazidime activity has been admixed to

20 facilitate dissolution. The total sodium content of the mixture is approximately 54 mg (2.3 mEq)/g

21 of ceftazidime activity.

FORTAZ in sterile crystalline form is supplied in vials equivalent to 500 mg, 1 g, 2 g, or 6 g of anhydrous ceftazidime and in ADD-Vantage[®] vials equivalent to 1 or 2 g of anhydrous

24 ceftazidime. Solutions of FORTAZ range in color from light yellow to amber, depending on the

diluent and volume used. The pH of freshly constituted solutions usually ranges from 5 to 8.

26 FORTAZ is available as a frozen, iso-osmotic, sterile, nonpyrogenic solution with 1 or 2 g of

27 ceftazidime as ceftazidime sodium premixed with approximately 2.2 or 1.6 g, respectively, of 28 dextrose hydrous, USP. Dextrose has been added to adjust the osmolality. Sodium hydroxide is 29 used to adjust pH and neutralize ceftazidime pentahydrate free acid to the sodium salt. The pH 30 may have been adjusted with hydrochloric acid. Solutions of premixed FORTAZ range in color 31 from light yellow to amber. The solution is intended for intravenous (IV) use after thawing to 32 room temperature. The osmolality of the solution is approximately 300 mOsmol/kg, and the pH of 33 thawed solutions ranges from 5 to 7.5. 34 The plastic container for the frozen solution is fabricated from a specially designed multilayer 35 plastic, PL 2040. Solutions are in contact with the polyethylene layer of this container and can 36 leach out certain chemical components of the plastic in very small amounts within the expiration 37 period. The suitability of the plastic has been confirmed in tests in animals according to USP

38 biological tests for plastic containers as well as by tissue culture toxicity studies.

39

40 CLINICAL PHARMACOLOGY: After IV administration of 500-mg and 1-g doses of
41 ceftazidime over 5 minutes to normal adult male volunteers, mean peak serum concentrations of
42 45 and 90 mcg/mL, respectively, were achieved. After IV infusion of 500-mg, 1-g, and 2-g doses
43 of ceftazidime over 20 to 30 minutes to normal adult male volunteers, mean peak serum
44 concentrations of 42, 69, and 170 mcg/mL, respectively, were achieved. The average serum
45 concentrations following IV infusion of 500-mg, 1-g, and 2-g doses to these volunteers over an
46 8-hour interval are given in Table 1.

- 47
- 48

 Table 1: Average Serum Concentrations of Ceftazidime

Ceftazidime	Serum Concentrations (mcg/mL)				
IV Dose	0.5 h	1 h	2 h	4 h	8 h
500 mg	42	25	12	6	2
1 g	60	39	23	11	3
2 g	129	75	42	13	5

49

50 The absorption and elimination of ceftazidime were directly proportional to the size of the dose.

51 The half-life following IV administration was approximately 1.9 hours. Less than 10% of

52 ceftazidime was protein bound. The degree of protein binding was independent of concentration. 53 There was no evidence of accumulation of ceftazidime in the serum in individuals with normal 54 renal function following multiple IV doses of 1 and 2 g every 8 hours for 10 days. 55 Following intramuscular (IM) administration of 500-mg and 1-g doses of ceftazidime to normal 56 adult volunteers, the mean peak serum concentrations were 17 and 39 mcg/mL, respectively, at 57 approximately 1 hour. Serum concentrations remained above 4 mcg/mL for 6 and 8 hours after the 58 IM administration of 500-mg and 1-g doses, respectively. The half-life of ceftazidime in these 59 volunteers was approximately 2 hours. 60 The presence of hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in 61 individuals administered 2 g intravenously every 8 hours for 5 days. Therefore, a dosage 62 adjustment from the normal recommended dosage is not required for patients with hepatic 63 dysfunction, provided renal function is not impaired. 64 Approximately 80% to 90% of an IM or IV dose of ceftazidime is excreted unchanged by the 65 kidneys over a 24-hour period. After the IV administration of single 500-mg or 1-g doses, 66 approximately 50% of the dose appeared in the urine in the first 2 hours. An additional 20% was 67 excreted between 2 and 4 hours after dosing, and approximately another 12% of the dose appeared 68 in the urine between 4 and 8 hours later. The elimination of ceftazidime by the kidneys resulted in 69 high therapeutic concentrations in the urine. 70 The mean renal clearance of ceftazidime was approximately 100 mL/min. The calculated 71 plasma clearance of approximately 115 mL/min indicated nearly complete elimination of 72 ceftazidime by the renal route. Administration of probenecid before dosing had no effect on the 73 elimination kinetics of ceftazidime. This suggested that ceftazidime is eliminated by glomerular 74 filtration and is not actively secreted by renal tubular mechanisms. 75 Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly 76 prolonged in patients with impaired renal function. Consequently, dosage adjustments in such 77 patients as described in the DOSAGE AND ADMINISTRATION section are suggested. Therapeutic concentrations of ceftazidime are achieved in the following body tissues and fluids. 78 79

FORTAZ[®] (ceftazidime for injection) FORTAZ[®] (ceftazidime sodium injection) Table 2: Ceftazidime Concentrations in Body Tissues and Fluids

			Time of	Average Tissue
		No. of	Sample	or Fluid Level
Tissue or Fluid	Dose/Route	Patients	Postdose	(mcg/mL or mcg/g)
Urine	500 mg IM	6	0-2 h	2,100.0
	2 g IV	6	0-2 h	12,000.0
Bile	2 g IV	3	90 min	36.4
Synovial fluid	2 g IV	13	2 h	25.6
Peritoneal fluid	2 g IV	8	2 h	48.6
Sputum	1 g IV	8	1 h	9.0
Cerebrospinal fluid	2 g q8h IV	5	120 min	9.8
(inflamed meninges)	2 g q8h IV	6	180 min	9.4
Aqueous humor	2 g IV	13	1-3 h	11.0
Blister fluid	1 g IV	7	2-3 h	19.7
Lymphatic fluid	1 g IV	7	2-3 h	23.4
Bone	2 g IV	8	0.67 h	31.1
Heart muscle	2 g IV	35	30-280 min	12.7
Skin	2 g IV	22	30-180 min	6.6
Skeletal muscle	2 g IV	35	30-280 min	9.4
Myometrium	2 g IV	31	1-2 h	18.7

⁸¹

82 Microbiology: Ceftazidime is bactericidal in action, exerting its effect by inhibition of enzymes 83 responsible for cell-wall synthesis. A wide range of gram-negative organisms is susceptible to 84 ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In 85 addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly 86 stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced 87 by both gram-negative and gram-positive organisms and, consequently, is active against many 88 strains resistant to ampicillin and other cephalosporins. 89 Ceftazidime has been shown to be active against the following organisms both in vitro and in

90 clinical infections (see INDICATIONS AND USAGE).

FORTAZ[®] (ceftazidime sodium injection) 91 Aerobes, Gram-negative: Citrobacter spp., including Citrobacter freundii and Citrobacter 92 diversus; Enterobacter spp., including Enterobacter cloacae and Enterobacter aerogenes; 93 *Escherichia coli*; *Haemophilus influenzae*, including ampicillin-resistant strains; *Klebsiella* spp. 94 (including Klebsiella pneumoniae); Neisseria meningitidis; Proteus mirabilis; Proteus vulgaris; 95 Pseudomonas spp. (including Pseudomonas aeruginosa); and Serratia spp. 96 Aerobes, Gram-positive: Staphylococcus aureus, including penicillinase- and 97 non-penicillinase-producing strains; *Streptococcus agalactiae* (group B streptococci); 98 Streptococcus pneumoniae; and Streptococcus pyogenes (group A beta-hemolytic streptococci). 99 Anaerobes: Bacteroides spp. (NOTE: many strains of Bacteroides fragilis are resistant). 100 Ceftazidime has been shown to be active *in vitro* against most strains of the following 101 organisms; however, the clinical significance of these data is unknown: Acinetobacter spp., 102 *Clostridium* spp. (not including *Clostridium difficile*), *Haemophilus parainfluenzae*, *Morganella* 103 morganii (formerly Proteus morganii), Neisseria gonorrhoeae, Peptococcus spp., 104 Peptostreptococcus spp., Providencia spp. (including Providencia rettgeri, formerly Proteus 105 rettgeri), Salmonella spp., Shigella spp., Staphylococcus epidermidis, and Yersinia enterocolitica. 106 Ceftazidime and the aminoglycosides have been shown to be synergistic *in vitro* against 107 Pseudomonas aeruginosa and the enterobacteriaceae. Ceftazidime and carbenicillin have also been 108 shown to be synergistic in vitro against Pseudomonas aeruginosa. 109 Ceftazidime is not active in vitro against methicillin-resistant staphylococci, Streptococcus 110 faecalis and many other enterococci, Listeria monocytogenes, Campylobacter spp., or Clostridium 111 difficile. 112 Susceptibility Tests: Diffusion Techniques: Quantitative methods that require measurement of zone diameters give an estimate of antibiotic susceptibility. One such procedure¹⁻³ has been 113 114 recommended for use with disks to test susceptibility to ceftazidime. 115 Reports from the laboratory giving results of the standard single-disk susceptibility test with a 116 30-mcg ceftazidime disk should be interpreted according to the following criteria: 117 Susceptible organisms produce zones of 18 mm or greater, indicating that the test organism 118 is likely to respond to therapy.

119 Organisms that produce zones of 15 to 17 mm are expected to be susceptible if high dosage 120 is used or if the infection is confined to tissues and fluids (e.g., urine) in which high antibiotic

121 levels are attained.

Resistant organisms produce zones of 14 mm or less, indicating that other therapy should beselected.

124 Organisms should be tested with the ceftazidime disk since ceftazidime has been shown by *in*

125 *vitro* tests to be active against certain strains found resistant when other beta-lactam disks are used.

126 Standardized procedures require the use of laboratory control organisms. The 30-mcg

127 ceftazidime disk should give zone diameters between 25 and 32 mm for Escherichia coli

128 ATCC 25922. For *Pseudomonas aeruginosa* ATCC 27853, the zone diameters should be between

129 22 and 29 mm. For *Staphylococcus aureus* ATCC 25923, the zone diameters should be between

130 16 and 20 mm.

131 Dilution Techniques: In other susceptibility testing procedures, e.g., ICS agar dilution or the 132 equivalent, a bacterial isolate may be considered susceptible if the minimum inhibitory 133 concentration (MIC) value for ceftazidime is not more than 16 mcg/mL. Organisms are considered 134 resistant to ceftazidime if the MIC is $\geq 64 \text{ mcg/mL}$. Organisms having an MIC value of 135 <64 mcg/mL but >16 mcg/mL are expected to be susceptible if high dosage is used or if the 136 infection is confined to tissues and fluids (e.g., urine) in which high antibiotic levels are attained. 137 As with standard diffusion methods, dilution procedures require the use of laboratory control 138 organisms. Standard ceftazidime powder should give MIC values in the range of 4 to 16 mcg/mL 139 for Staphylococcus aureus ATCC 25923. For Escherichia coli ATCC 25922, the MIC range 140 should be between 0.125 and 0.5 mcg/mL. For *Pseudomonas aeruginosa* ATCC 27853, the MIC 141 range should be between 0.5 and 2 mcg/mL.

142

143 INDICATIONS AND USAGE: FORTAZ is indicated for the treatment of patients with
144 infections caused by susceptible strains of the designated organisms in the following diseases:

145 **1. Lower Respiratory Tract Infections,** including pneumonia, caused by *Pseudomonas*

146 *aeruginosa* and other *Pseudomonas* spp.; *Haemophilus influenzae*, including

147 ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia

148 *coli*; *Serratia* spp.; *Citrobacter* spp.; *Streptococcus pneumoniae*; and *Staphylococcus aureus*

149 (methicillin-susceptible strains).

150 2. Skin and Skin-Structure Infections caused by *Pseudomonas aeruginosa*; *Klebsiella* spp.;

- 151 *Escherichia coli*; *Proteus* spp., including *Proteus mirabilis* and indole-positive *Proteus*;
- 152 Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and
- 153 *Streptococcus pyogenes* (group A beta-hemolytic streptococci).
- 154 **3.** Urinary Tract Infections, both complicated and uncomplicated, caused by *Pseudomonas*
- 155 *aeruginosa; Enterobacter* spp.; *Proteus* spp., including *Proteus mirabilis* and indole-positive
- 156 *Proteus*; *Klebsiella* spp.; and *Escherichia coli*.
- 157 **4. Bacterial Septicemia** caused by *Pseudomonas aeruginosa*, *Klebsiella* spp., *Haemophilus*
- 158 *influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus*
- 159 *aureus* (methicillin-susceptible strains).
- 160 **5. Bone and Joint Infections** caused by *Pseudomonas aeruginosa, Klebsiella* spp., *Enterobacter*
- 161 spp., and *Staphylococcus aureus* (methicillin-susceptible strains).
- 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the
 female genital tract caused by *Escherichia coli*.
- 164 **7. Intra-abdominal Infections,** including peritonitis caused by *Escherichia coli*, *Klebsiella* spp.,
- and *Staphylococcus aureus* (methicillin-susceptible strains) and polymicrobial infections caused
- by aerobic and anaerobic organisms and *Bacteroides* spp. (many strains of *Bacteroides fragilis*are resistant).

168 8. Central Nervous System Infections, including meningitis, caused by *Haemophilus influenzae* 169 and *Neisseria meningitidis*. Ceftazidime has also been used successfully in a limited number of

170 cases of meningitis due to *Pseudomonas aeruginosa* and *Streptococcus pneumoniae*.

171 Specimens for bacterial cultures should be obtained before therapy in order to isolate and

172 identify causative organisms and to determine their susceptibility to ceftazidime. Therapy may be

173 instituted before results of susceptibility studies are known; however, once these results become

available, the antibiotic treatment should be adjusted accordingly.

175 FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been

176 used successfully in clinical trials as empiric therapy in cases where various concomitant therapies

- 177 with other antibiotics have been used.
- 178 FORTAZ may also be used concomitantly with other antibiotics, such as aminoglycosides,
- 179 vancomycin, and clindamycin; in severe and life-threatening infections; and in the
- 180 immunocompromised patient. When such concomitant treatment is appropriate, prescribing

- 181 information in the labeling for the other antibiotics should be followed. The dose depends on the
- 182 severity of the infection and the patient's condition.
- 183
- 184 **CONTRAINDICATIONS:** FORTAZ is contraindicated in patients who have shown
- 185 hypersensitivity to ceftazidime or the cephalosporin group of antibiotics.
- 186
- 187 WARNINGS: BEFORE THERAPY WITH FORTAZ IS INSTITUTED, CAREFUL INQUIRY
- 188 SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS
- 189 HYPERSENSITIVITY REACTIONS TO CEFTAZIDIME, CEPHALOSPORINS, PENICILLINS,
- 190 OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE
- 191 PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-HYPERSENSITIVITY
- 192 AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND
- 193 MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN
- 194 ALLERGY. IF AN ALLERGIC REACTION TO FORTAZ OCCURS, DISCONTINUE THE
- 195 DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE
- 196 TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING
- 197 OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES,
- 198 AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.
- 199 Pseudomembranous colitis has been reported with nearly all antibacterial agents,
- 200 including ceftazidime, and may range in severity from mild to life threatening. Therefore, it
- 201 is important to consider this diagnosis in patients who present with diarrhea subsequent to
- 202 the administration of antibacterial agents.
- Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by *Clostridium difficile* is one primary cause of "antibiotic-associated colitis."
- After the diagnosis of pseudomembranous colitis has been established, appropriate therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against *Clostridium difficile* colitis.

- 211 Elevated levels of ceftazidime in patients with renal insufficiency can lead to seizures,
- encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia (see
- 213 PRECAUTIONS).
- 214

215 **PRECAUTIONS:**

General: High and prolonged serum ceftazidime concentrations can occur from usual dosages in patients with transient or persistent reduction of urinary output because of renal insufficiency. The total daily dosage should be reduced when ceftazidime is administered to patients with renal insufficiency (see DOSAGE AND ADMINISTRATION). Elevated levels of ceftazidime in these patients can lead to seizures, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia. Continued dosage should be determined by degree of renal impairment, severity of

222 infection, and susceptibility of the causative organisms.

As with other antibiotics, prolonged use of FORTAZ may result in overgrowth of

224 nonsusceptible organisms. Repeated evaluation of the patient's condition is essential. If

superinfection occurs during therapy, appropriate measures should be taken.

Inducible type I beta-lactamase resistance has been noted with some organisms (e.g.,

227 Enterobacter spp., Pseudomonas spp., and Serratia spp.). As with other extended-spectrum

beta-lactam antibiotics, resistance can develop during therapy, leading to clinical failure in some

229 cases. When treating infections caused by these organisms, periodic susceptibility testing should

230 be performed when clinically appropriate. If patients fail to respond to monotherapy, an

aminoglycoside or similar agent should be considered.

Cephalosporins may be associated with a fall in prothrombin activity. Those at risk include
patients with renal and hepatic impairment, or poor nutritional state, as well as patients receiving a
protracted course of antimicrobial therapy. Prothrombin time should be monitored in patients at

risk and exogenous vitamin K administered as indicated.

FORTAZ should be prescribed with caution in individuals with a history of gastrointestinaldisease, particularly colitis.

238 Distal necrosis can occur after inadvertent intra-arterial administration of ceftazidime.

239 Drug Interactions: Nephrotoxicity has been reported following concomitant administration of

240 cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide. Renal

- function should be carefully monitored, especially if higher dosages of the aminoglycosides are to
- be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity
- of aminoglycosidic antibiotics. Nephrotoxicity and ototoxicity were not noted when ceftazidime

244 was given alone in clinical trials.

- 245 Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including
- 246 ceftazidime, based on *in vitro* studies and time kill curves with enteric gram-negative bacilli. Due
- to the possibility of antagonism *in vivo*, particularly when bactericidal activity is desired, this
- 248 drug combination should be avoided.
- 249 **Drug/Laboratory Test Interactions:** The administration of ceftazidime may result in a

250 false-positive reaction for glucose in the urine when using CLINITEST[®] tablets, Benedict's

solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose

252 oxidase reactions (such as CLINISTIX[®]) be used.

253 Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not

been performed to evaluate carcinogenic potential. However, a mouse Micronucleus test and an
Ames test were both negative for mutagenic effects.

256 **Pregnancy:** *Teratogenic Effects:* Pregnancy Category B. Reproduction studies have been

257 performed in mice and rats at doses up to 40 times the human dose and have revealed no evidence

- 258 of impaired fertility or harm to the fetus due to FORTAZ. There are, however, no adequate and
- 259 well-controlled studies in pregnant women. Because animal reproduction studies are not always
- 260 predictive of human response, this drug should be used during pregnancy only if clearly needed.
- 261 Nursing Mothers: Ceftazidime is excreted in human milk in low concentrations. Caution should

262 be exercised when FORTAZ is administered to a nursing woman.

263 **Pediatric Use:** (see DOSAGE AND ADMINISTRATION).

264

ADVERSE REACTIONS: Ceftazidime is generally well tolerated. The incidence of adverse
 reactions associated with the administration of ceftazidime was low in clinical trials. The most
 common were local reactions following IV injection and allergic and gastrointestinal reactions.
 Other adverse reactions were encountered infrequently. No disulfiramlike reactions were reported.

- 269 The following adverse effects from clinical trials were considered to be either related to
- 270 ceftazidime therapy or were of uncertain etiology:

- Local Effects, reported in fewer than 2% of patients, were phlebitis and inflammation at the site ofinjection (1 in 69 patients).
- 273 Hypersensitivity Reactions, reported in 2% of patients, were pruritus, rash, and fever. Immediate
- 274 reactions, generally manifested by rash and/or pruritus, occurred in 1 in 285 patients. Toxic
- 275 epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have also been
- 276 reported with cephalosporin antibiotics, including ceftazidime. Angioedema and anaphylaxis
- 277 (bronchospasm and/or hypotension) have been reported very rarely.
- 278 Gastrointestinal Symptoms, reported in fewer than 2% of patients, were diarrhea (1 in 78),
- 279 nausea (1 in 156), vomiting (1 in 500), and abdominal pain (1 in 416). The onset of
- 280 pseudomembranous colitis symptoms may occur during or after treatment (see WARNINGS).
- 281 Central Nervous System Reactions (fewer than 1%) included headache, dizziness, and
- 282 paresthesia. Seizures have been reported with several cephalosporins, including ceftazidime. In
- addition, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been
- reported in renally impaired patients treated with unadjusted dosing regimens of ceftazidime (see
- 285 PRECAUTIONS: General).
- Less Frequent Adverse Events (fewer than 1%) were candidiasis (including oral thrush) and
 vaginitis.
- 288 Hematologic: Rare cases of hemolytic anemia have been reported.
- 289 Laboratory Test Changes noted during clinical trials with FORTAZ were transient and included:
- eosinophilia (1 in 13), positive Coombs test without hemolysis (1 in 23), thrombocytosis (1 in 45),
- and slight elevations in one or more of the hepatic enzymes, aspartate aminotransferase (AST,
- 292 SGOT) (1 in 16), alanine aminotransferase (ALT, SGPT) (1 in 15), LDH (1 in 18), GGT (1 in 19),
- and alkaline phosphatase (1 in 23). As with some other cephalosporins, transient elevations of
- blood urea, blood urea nitrogen, and/or serum creatinine were observed occasionally. Transient
- leukopenia, neutropenia, agranulocytosis, thrombocytopenia, and lymphocytosis were seen veryrarely.
- 297
- 298 POSTMARKETING EXPERIENCE WITH FORTAZ PRODUCTS: In addition to the
 adverse events reported during clinical trials, the following events have been observed during
- 300 clinical practice in patients treated with FORTAZ and were reported spontaneously. For some of

- 301 these events, data are insufficient to allow an estimate of incidence or to establish causation. General: Anaphylax
- 302 *Hepatobiliary Tract:* Hyperbilirubinemia, jaundice.
- 303 *Renal and Genitourinary:* Renal impairment.
- 304 Cephalosporin-Class Adverse Reactions: In addition to the adverse reactions listed above that
- 305 have been observed in patients treated with ceftazidime, the following adverse reactions and
- 306 altered laboratory tests have been reported for cephalosporin-class antibiotics:
- 307 *Adverse Reactions:* Colitis, toxic nephropathy, hepatic dysfunction including cholestasis,
- 308 aplastic anemia, hemorrhage.
- 309 *Altered Laboratory Tests:* Prolonged prothrombin time, false-positive test for urinary
- 310 glucose, pancytopenia.
- 311
- 312 **OVERDOSAGE:** Ceftazidime overdosage has occurred in patients with renal failure. Reactions
- 313 have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.
- 314 Patients who receive an acute overdosage should be carefully observed and given supportive
- 315 treatment. In the presence of renal insufficiency, hemodialysis or peritoneal dialysis may aid in the
- 316 removal of ceftazidime from the body.
- 317

318 DOSAGE AND ADMINISTRATION:

- 319 **Dosage:** The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8
- to 12 hours. The dosage and route should be determined by the susceptibility of the causative
- 321 organisms, the severity of infection, and the condition and renal function of the patient.
- The guidelines for dosage of FORTAZ are listed in Table 3. The following dosage schedule is recommended.
- 324

FORTAZ[®] (ceftazidime for injection) FORTAZ[®] (ceftazidime sodium injection) Table 3: Recommended Dosage Schedule

	Dose	Frequency
Adults		
Usual recommended dosage	1 gram IV or IM	q8-12h
Uncomplicated urinary tract infections	250 mg IV or IM	q12h
Bone and joint infections	2 grams IV	q12h
Complicated urinary tract infections	500 mg IV or IM	q8-12h
Uncomplicated pneumonia; mild skin and	500 mg-1 gram IV or IM	q8h
skin-structure infections		
Serious gynecologic and intra-abdominal	2 grams IV	q8h
infections		
Meningitis	2 grams IV	q8h
Very severe life-threatening infections,	2 grams IV	q8h
especially in immunocompromised patients		
Lung infections caused by Pseudomonas spp.	30-50 mg/kg IV to a maximum	q8h
in patients with cystic fibrosis with normal	of 6 grams per day	
renal function [*]		
Neonates (0-4 weeks)	30 mg/kg IV	q12h
Infants and children	30-50 mg/kg IV to a maximum	q8h
(1 month-12 years)	of 6 grams per day ^{\dagger}	
*Although clinical improvement has been shown	n, bacteriologic cures cannot be ex	pected in
patients with chronic respiratory disease and cy	vstic fibrosis.	
The higher dose should be reserved for immuno	ocompromised pediatric patients of	r pediatric

329 patients with cystic fibrosis or meningitis.

330

326

327

328

Impaired Hepatic Function: No adjustment in dosage is required for patients with hepatic
 dysfunction.

333 *Impaired Renal Function:* Ceftazidime is excreted by the kidneys, almost exclusively by

334 glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration rate

335 [GFR] <50 mL/min), it is recommended that the dosage of ceftazidime be reduced to compensate

- 336 for its slower excretion. In patients with suspected renal insufficiency, an initial loading dose of
- 337 1 gram of FORTAZ may be given. An estimate of GFR should be made to determine the
- appropriate maintenance dosage. The recommended dosage is presented in Table 4.
- 339

340 Table 4: Recommended Maintenance Dosages of FORTAZ in Renal Insufficiency

341 NOTE: IF THE DOSE RECOMMENDED IN TABLE 3 ABOVE IS LOWER THAN THAT

342 RECOMMENDED FOR PATIENTS WITH RENAL INSUFFICIENCY AS OUTLINED IN

343 TABLE 4, THE LOWER DOSE SHOULD BE USED.

Creatinine Clearance	Recommended Unit Dose	
(mL/min)	of FORTAZ	Frequency of Dosing
50-31	1 gram	q12h
30-16	1 gram	q24h
15-6	500 mg	q24h
<5	500 mg	q48h

344

When only serum creatinine is available, the following formula (Cockcroft's equation)⁴ may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function:

348

349 Males: Creatinine clearance (mL/min) = Weight (kg) x (140 - age)350 72 x serum creatinine (mg/dL)

351 Females: 0.85 x male value

352

In patients with severe infections who would normally receive 6 grams of FORTAZ daily were it not for renal insufficiency, the unit dose given in the table above may be increased by 50% or the dosing frequency may be increased appropriately. Further dosing should be determined by therapeutic monitoring, severity of the infection, and susceptibility of the causative organism. In pediatric patients as for adults, the creatinine clearance should be adjusted for body surface area or lean body mass, and the dosing frequency should be reduced in cases of renal insufficiency. In patients undergoing hemodialysis, a loading dose of 1 gram is recommended, followed by

360 1 gram after each hemodialysis period.

361 FORTAZ can also be used in patients undergoing intraperitoneal dialysis and continuous

ambulatory peritoneal dialysis. In such patients, a loading dose of 1 gram of FORTAZ may be

363 given, followed by 500 mg every 24 hours. In addition to IV use, FORTAZ can be incorporated in

the dialysis fluid at a concentration of 250 mg for 2 L of dialysis fluid.

365 Note: Generally FORTAZ should be continued for 2 days after the signs and symptoms of

366 infection have disappeared, but in complicated infections longer therapy may be required.

367 Administration: FORTAZ may be given intravenously or by deep IM injection into a large

368 muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh.

369 Intra-arterial administration should be avoided (see PRECAUTIONS).

370 *Intramuscular Administration:* For IM administration, FORTAZ should be constituted with 371 one of the following diluents: Sterile Water for Injection, Bacteriostatic Water for Injection, or

372 0.5% or 1% Lidocaine Hydrochloride Injection. Refer to Table 5.

373 *Intravenous Administration:* The IV route is preferable for patients with bacterial septicemia, 374 bacterial meningitis, peritonitis, or other severe or life-threatening infections, or for patients who 375 may be poor risks because of lowered resistance resulting from such debilitating conditions as 376 malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present 377 or pending.

378 For direct intermittent IV administration, constitute FORTAZ as directed in Table 5 with 379 Sterile Water for Injection. Slowly inject directly into the vein over a period of 3 to 5 minutes or 380 give through the tubing of an administration set while the patient is also receiving one of the 381 compatible IV fluids (see COMPATIBILITY AND STABILITY).

382 For IV infusion, constitute the 1- or 2-gram infusion pack with 100 mL of Sterile Water for 383 Injection or one of the compatible IV fluids listed under the COMPATIBILITY AND STABILITY 384 section. Alternatively, constitute the 500-mg, 1-gram, or 2-gram vial and add an appropriate 385 quantity of the resulting solution to an IV container with one of the compatible IV fluids.

Intermittent IV infusion with a Y-type administration set can be accomplished with
 compatible solutions. However, during infusion of a solution containing ceftazidime, it is desirable
 to discontinue the other solution.

ADD-Vantage vials are to be constituted only with 50 or 100 mL of 5% Dextrose Injection,

390 0.9% Sodium Chloride Injection, or 0.45% Sodium Chloride Injection in Abbott ADD-Vantage

391 flexible diluent containers (see Instructions for Constitution). ADD-Vantage vials that have been

392 joined to Abbott ADD-Vantage diluent containers and activated to dissolve the drug are stable for

393 24 hours at room temperature or for 7 days under refrigeration. Joined vials that have not been

activated may be used within a 14-day period; this period corresponds to that for use of Abbott

395 ADD-Vantage containers following removal of the outer packaging (overwrap).

396 Freezing solutions of FORTAZ in the ADD-Vantage system is not recommended.

- 397
- 398

Table 5: Preparation of Solutions of FORTAZ

			Approximate
	Amount of Diluent	Approximate	Ceftazidime
	to be Added	Available Volume	Concentration
Size	(mL)	(mL)	(mg/mL)
Intramuscular			
500-mg vial	1.5	1.8	280
1-gram vial	3.0	3.6	280
Intravenous			
500-mg vial	5.0	5.3	100
1-gram vial	10.0	10.6	100
2-gram vial	10.0	11.5	170
Infusion pack			
1-gram vial	100^{*}	100	10
2-gram vial	100^{*}	100	20
Pharmacy bulk package			
6-gram vial	26	30	200

^{*}Note: Addition should be in 2 stages (see Instructions for Constitution).

400

401 All vials of FORTAZ as supplied are under reduced pressure. When FORTAZ is dissolved,

402 carbon dioxide is released and a positive pressure develops. For ease of use please follow the

- 403 recommended techniques of constitution described on the detachable Instructions for Constitution404 section of this insert.
- 405 Solutions of FORTAZ, like those of most beta-lactam antibiotics, should not be added to
- 406 solutions of aminoglycoside antibiotics because of potential interaction.
- 407 However, if concurrent therapy with FORTAZ and an aminoglycoside is indicated, each of
- 408 these antibiotics can be administered separately to the same patient.

409 Directions for Use of FORTAZ Frozen in GALAXY[®] Plastic Containers: FORTAZ supplied

- 410 as a frozen, sterile, iso-osmotic, nonpyrogenic solution in plastic containers is to be administered
- 411 after thawing either as a continuous or intermittent IV infusion. The thawed solution is stable for
- 412 24 hours at room temperature or for 7 days if stored under refrigeration. **Do not refreeze.**
- 413 Thaw container at room temperature $(25^{\circ}C)$ or under refrigeration $(5^{\circ}C)$. Do not force thaw by
- 414 immersion in water baths or by microwave irradiation. Components of the solution may precipitate
- 415 in the frozen state and will dissolve upon reaching room temperature with little or no agitation.
- 416 Potency is not affected. Mix after solution has reached room temperature. Check for minute leaks
- 417 by squeezing bag firmly. Discard bag if leaks are found as sterility may be impaired. Do not add
- 418 supplementary medication. Do not use unless solution is clear and seal is intact.
- 419 Use sterile equipment.
- 420 *Caution:* Do not use plastic containers in series connections. Such use could result in air
- 421 embolism due to residual air being drawn from the primary container before administration of the
- 422 fluid from the secondary container is complete.

423 **Preparation for Administration:**

- 424 1. Suspend container from eyelet support.
- 425 2. Remove protector from outlet port at bottom of container.
- 426 3. Attach administration set. Refer to complete directions accompanying set.
- 427

428 COMPATIBILITY AND STABILITY:

- 429 Intramuscular: FORTAZ, when constituted as directed with Sterile Water for Injection,
- 430 Bacteriostatic Water for Injection, or 0.5% or 1% Lidocaine Hydrochloride Injection, maintains
- 431 satisfactory potency for 24 hours at room temperature or for 7 days under refrigeration. Solutions
- 432 in Sterile Water for Injection that are frozen immediately after constitution in the original

433 container are stable for 3 months when stored at -20°C. Once thawed, solutions should not be
434 refrozen. Thawed solutions may be stored for up to 8 hours at room temperature or for 4 days in a
435 refrigerator.

436 Intravenous: FORTAZ, when constituted as directed with Sterile Water for Injection, maintains 437 satisfactory potency for 24 hours at room temperature or for 7 days under refrigeration. Solutions 438 in Sterile Water for Injection in the infusion vial or in 0.9% Sodium Chloride Injection in VIAFLEX[®] small-volume containers that are frozen immediately after constitution are stable for 439 440 6 months when stored at -20°C. Do not force thaw by immersion in water baths or by microwave 441 irradiation. Once thawed, solutions should not be refrozen. Thawed solutions may be stored for up 442 to 24 hours at room temperature or for 7 days in a refrigerator. More concentrated solutions in 443 Sterile Water for Injection in the original container that are frozen immediately after constitution 444 are stable for 3 months when stored at -20°C. Once thawed, solutions should not be refrozen. 445 Thawed solutions may be stored for up to 8 hours at room temperature or for 4 days in a 446 refrigerator.

447 FORTAZ is compatible with the more commonly used IV infusion fluids. Solutions at

448 concentrations between 1 and 40 mg/mL in 0.9% Sodium Chloride Injection; 1/6 M Sodium

449 Lactate Injection; 5% Dextrose Injection; 5% Dextrose and 0.225% Sodium Chloride Injection;

450 5% Dextrose and 0.45% Sodium Chloride Injection; 5% Dextrose and 0.9% Sodium Chloride

451 Injection; 10% Dextrose Injection; Ringer's Injection, USP; Lactated Ringer's Injection, USP; 10%

452 Invert Sugar in Water for Injection; and NORMOSOL[®]-M in 5% Dextrose Injection may be stored

453 for up to 24 hours at room temperature or for 7 days if refrigerated.

454 The 1- and 2-g FORTAZ ADD-Vantage vials, when diluted in 50 or 100 mL of 5% Dextrose

455 Injection, 0.9% Sodium Chloride Injection, or 0.45% Sodium Chloride Injection, may be stored for

456 up to 24 hours at room temperature or for 7 days under refrigeration.

457 FORTAZ is less stable in Sodium Bicarbonate Injection than in other IV fluids. It is not

458 recommended as a diluent. Solutions of FORTAZ in 5% Dextrose Injection and 0.9% Sodium

459 Chloride Injection are stable for at least 6 hours at room temperature in plastic tubing, drip

460 chambers, and volume control devices of common IV infusion sets.

461 Ceftazidime at a concentration of 4 mg/mL has been found compatible for 24 hours at room

462 temperature or for 7 days under refrigeration in 0.9% Sodium Chloride Injection or 5% Dextrose

- 463 Injection when admixed with: cefuroxime sodium (ZINACEF[®]) 3 mg/mL; heparin 10 or 50 U/mL;
 464 or potassium chloride 10 or 40 mEq/L.
- 465 Vancomycin solution exhibits a physical incompatibility when mixed with a number of drugs,
- 466 including ceftazidime. The likelihood of precipitation with ceftazidime is dependent on the
- 467 concentrations of vancomycin and ceftazidime present. It is therefore recommended, when both
- 468 drugs are to be administered by intermittent IV infusion, that they be given separately, flushing the
- 469 IV lines (with 1 of the compatible IV fluids) between the administration of these 2 agents.
- 470 Note: Parenteral drug products should be inspected visually for particulate matter before
- 471 administration whenever solution and container permit.
- 472 As with other cephalosporins, FORTAZ powder as well as solutions tend to darken, depending
- 473 on storage conditions; within the stated recommendations, however, product potency is not
- 474 adversely affected.
- 475

476 **HOW SUPPLIED:** FORTAZ in the dry state should be stored between 15° and 30°C (59° and

- 477 86°F) and protected from light. FORTAZ is a dry, white to off-white powder supplied in vials and
- 478 infusion packs as follows:
- 479 NDC 0173-0377-31 500-mg^{*} Vial (Tray of 25)
- 480 NDC 0173-0378-35 1-g* Vial (Tray of 25)
- 481 NDC 0173-0379-34 2-g* Vial (Tray of 10)
- 482 NDC 0173-0380-32 1-g^{*} Infusion Pack (Tray of 10)
- 483 NDC 0173-0381-32 2-g^{*} Infusion Pack (Tray of 10)
- 484 NDC 0173-0382-37 6-g^{*} Pharmacy Bulk Package (Tray of 6)
- 485 NDC 0173-0434-00 1-g ADD-Vantage[®] Vial (Tray of 25)
- 486 NDC 0173-0435-00 2-g ADD-Vantage[®] Vial (Tray of 10)
- 487 (The above ADD-Vantage vials are to be used only with Abbott ADD-Vantage diluent containers.)
- 488 FORTAZ frozen as a premixed solution of ceftazidime sodium should not be stored above
- 489 -20°C. FORTAZ is supplied frozen in 50-mL, single-dose, plastic containers as follows:
- 490 NDC 0173-0412-00 1-g^{*} Plastic Container (Carton of 24)
- 491 NDC 0173-0413-00 2-g^{*} Plastic Container (Carton of 24)
- 492 ^{*}Equivalent to anhydrous ceftazidime.

	FORTAZ [®] (ceftazidime sodium injection)
493	
494	REFERENCES:
495	1. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a
496	standardized single disk method. Am J Clin Pathol. 1966;45:493-496.
497	2. National Committee for Clinical Laboratory Standards. Approved Standard: Performance
498	Standards for Antimicrobial Disc Susceptibility Tests. (M2-A3). December 1984.
499	3. Certification procedure for antibiotic sensitivity discs (21 CFR 460.1). Federal Register. May
500	30, 1974;39:19182-19184.
501	4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron.
502	1976;16:31-41.
503	
504	
505	
	gsk GlaxoSmithKline
506	Glaxosmitrixine
507	GlaxoSmithKline
508	FORTAZ [®] (ceftazidime for injection):
509	GlaxoSmithKline
510	Research Triangle Park, NC 27709
511	
512	FORTAZ [®] (ceftazidime sodium injection):
513	Manufactured for GlaxoSmithKline
514	Research Triangle Park, NC 27709
515	by Baxter Healthcare Corporation,
516	Deerfield, IL 60015
517	
518	FORTAZ and ZINACEF are registered trademarks of GlaxoSmithKline.
519	ADD-Vantage is a registered trademark of Abbott Laboratories.
520	CLINITEST and CLINISTIX are registered trademarks of Ames Division, Miles Laboratories, Inc.
521	

FORTAZ[®] (ceftazidime for injection)

522 GALAXY and VIAFLEX are registered trademarks of Baxter International Inc.

523

524 Date of Issue

RL-

TEAR AWAY

FORTAZ[®]

(ceftazidime for injection)

Instructions for Constitution

Vials: 500 mg IM/IV, 1 g IM/IV, 2 g IV

- Insert the syringe needle through the vial closure and inject the recommended volume of diluent. The vacuum may assist entry of the diluent. Remove the syringe needle.
- 2. Shake to dissolve; a clear solution will be obtained in 1 to 2 minutes.
- 3. Invert the vial. Ensuring that the syringe plunger is fully depressed, insert the needle through the vial closure and withdraw the total volume of solution into the syringe (the pressure in the vial may aid withdrawal). Ensure that the needle remains within the solution and does not enter the headspace. The withdrawn solution may contain some bubbles of carbon dioxide.

Note: As with the administration of all parenteral products, accumulated gases should be expressed from the syringe immediately before injection of FORTAZ.

Infusion Pack: 1 g, 2 g

- 1. Insert the syringe needle through the vial closure and inject 10 mL of diluent. The vacuum may assist entry of the diluent. Remove the syringe needle.
- 2. Shake to dissolve; a clear solution will be obtained in 1 to 2 minutes.
- 3. Insert a gas-relief needle through the vial closure to relieve the internal pressure. With the gas-relief needle in position, add the remaining 90 mL of diluent. Remove the gas-relief needle and syringe needle; shake the vial and set up for infusion in the normal way.

Note: To preserve product sterility, it is important that a gas-relief needle is not inserted through the

vial closure before the product has dissolved.

ADD-Vantage[®] Vials: 1 g, 2 g

To Open Diluent Container:

Peel the corner of the ADD-Vantage diluent overwrap and remove flexible diluent container. Some opacity of the plastic flexible container due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

To Assemble Vial and Flexible Diluent Container (Use Aseptic Technique):

- 1. Remove the protective covers from the top of the vial and the vial port on the diluent container as follows:
 - a. To remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening (see Figure 1), then pull straight up to remove the cap (see Figure 2).
 Note: Once the breakaway cap has been removed, do not access vial with syringe.





Figure 1

Figure 2

b. To remove the vial port cover, grasp the tab on the pull ring, pull up to break the three tie strings, then pull back to remove the cover (see Figure 3).

 Screw the vial into the vial port until it will go no further. THE VIAL MUST BE SCREWED IN TIGHTLY TO ASSURE A SEAL. This occurs approximately one-half turn (180°) after the first audible click (see Figure 4). The clicking sound does not assure a seal; the vial must be turned as far as it will go.

Note: Once vial is seated, do not attempt to remove (see Figure 4).






Figure 3

Figure 4

3.

Recheck the vial to assure that it is tight by trying to turn it further in the

direction of assembly.

4.

Label appropriately.

To Prepare Admixture:

- 1. Squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial.
- 2. With the other hand, push the drug vial down into the container, telescoping the walls of the container. Grasp the inner cap of the vial through the walls of the container (see Figure 5).
- 3. Pull the inner cap from the drug vial (see Figure 6). Verify that the rubber stopper has been pulled out, allowing the drug and diluent to mix.






Figure 6

4. Mix container contents thoroughly and use within the specified time.

Preparation for Administration (Use Aseptic Technique):

- 1. Confirm the activation and admixture of vial contents.
- 2. Check for leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired.
- 3. Close flow control clamp of administration set.

- 4. Remove cover from outlet port at bottom of container.
- 5. Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.

Note: See full directions on administration set carton.

- 6. Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings. Bend the loop outward to lock it in the upright position, then suspend container from hanger.
- 7. Squeeze and release drip chamber to establish proper fluid level in chamber.
- 8. Open flow control clamp and clear air from set. Close clamp.
- 9. Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.
- 10. Regulate rate of administration with flow control clamp.

WARNING: Do not use flexible container in series connections.

Pharmacy Bulk Package: 6 g

- 1. Insert the syringe needle through the vial closure and inject 26 mL of diluent. The vacuum may assist entry of the diluent. Remove the syringe needle.
- Shake to dissolve; a clear solution containing approximately 1 g of ceftazidime activity per 5 mL will be obtained in 1 to 2 minutes.
- 3. Insert a gas-relief needle through the vial closure to relieve the internal pressure. Remove the gas-relief needle before extracting any solution.

Note: To preserve product sterility, it is important that a gas-relief needle is *not* inserted through the vial closure before the product has dissolved.



GlaxoSmithKline Research Triangle Park, NC 27709

Date of Issue

RL-

PRODUCT INFORMATION

2 CEPTAZ[®]

3 (ceftazidime for injection)

- 4 L-arginine formulation
- 5

1

6 For Intravenous or Intramuscular Use

7


8 **DESCRIPTION:** Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for

9 parenteral administration. It is the pentahydrate of pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)](1-

10 carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-

11 en-3-yl]methyl]-, hydroxide, inner salt, $[6R-[6\alpha,7\beta(Z)]]$. It has the following structure:

12



- 13 14
- 15 The empirical formula is $C_{22}H_{32}N_6O_{12}S_2$, representing a molecular weight of 636.6.

16 CEPTAZ is a sterile, dry mixture of ceftazidime pentahydrate and L-arginine. The L-arginine

17 is at a concentration of 349 mg/g of ceftazidime activity. CEPTAZ dissolves without the

18 evolution of gas. The product contains no sodium ion. Solutions of CEPTAZ range in color from

19 light yellow to amber, depending on the diluent and volume used. The pH of freshly constituted

- 20 solutions usually ranges from 5 to 7.5.
- 21

CLINICAL PHARMACOLOGY: After intravenous (IV) administration of 500-mg and 1-g
doses of ceftazidime over 5 minutes to normal adult male volunteers, mean peak serum
concentrations of 45 and 90 mcg/mL, respectively, were achieved. After IV infusion of 500-mg,
1-g, and 2-g doses of ceftazidime over 20 to 30 minutes to normal adult male volunteers, mean
peak serum concentrations of 42, 69, and 170 mcg/mL, respectively, were achieved. The average
serum concentrations following IV infusion of 500-mg, 1-g, and 2-g doses to these volunteers

over an 8-hour interval are given in Table 1.

- 29
- 30

Table 1

Ceftazidime	Serum Concentrations (mcg/mL)				
IV Dose	0.5 h	1 h	2 h	4 h	8 h
500 mg	42	25	12	6	2
1 g	60	39	23	11	3
2 g	129	75	42	13	5

31

32 The absorption and elimination of ceftazidime were directly proportional to the size of the 33 dose. The half-life following IV administration was approximately 1.9 hours. Less than 10% of

34 ceftazidime was protein bound. The degree of protein binding was independent of concentration.

35 There was no evidence of accumulation of ceftazidime in the serum in individuals with normal

renal function following multiple IV doses of 1 and 2 g every 8 hours for 10 days.

37 Following intramuscular (IM) administration of 500-mg and 1-g doses of ceftazidime to

normal adult volunteers, the mean peak serum concentrations were 17 and 39 mcg/mL,

39 respectively, at approximately 1 hour. Serum concentrations remained above 4 mcg/mL for 6 and

40 8 hours after the IM administration of 500-mg and 1-g doses, respectively. The half-life of

41 ceftazidime in these volunteers was approximately 2 hours.

42 The presence of hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in

43 individuals administered 2 g intravenously every 8 hours for 5 days. Therefore, a dosage

44 adjustment from the normal recommended dosage is not required for patients with hepatic

45 dysfunction, provided renal function is not impaired.

46 Approximately 80% to 90% of an IM or IV dose of ceftazidime is excreted unchanged by the

47 kidneys over a 24-hour period. After the IV administration of single 500-mg or 1-g doses,

48 approximately 50% of the dose appeared in the urine in the first 2 hours. An additional 20% was

49 excreted between 2 and 4 hours after dosing, and approximately another 12% of the dose

50 appeared in the urine between 4 and 8 hours later. The elimination of ceftazidime by the kidneys

51 resulted in high therapeutic concentrations in the urine.

52 The mean renal clearance of ceftazidime was approximately 100 mL/min. The calculated

- 53 plasma clearance of approximately 115 mL/min indicated nearly complete elimination of
- 54 ceftazidime by the renal route. Administration of probenecid before dosing had no effect on the
- 55 elimination kinetics of ceftazidime. This suggested that ceftazidime is eliminated by glomerular
- 56 filtration and is not actively secreted by renal tubular mechanisms.
- 57 Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly
- 58 prolonged in patients with impaired renal function. Consequently, dosage adjustments in such
- 59 patients as described in the DOSAGE AND ADMINISTRATION section are suggested.
- 60 Ceftazidime concentrations achieved in specific body tissues and fluids are depicted in
- 61 Table 2.
- 62



Table 2: Ceftazidime Concentrations in Body Tissues and Fluids

				Average Tissue
			Time of	or Fluid Level
		No. of	Sample	(mcg/mL or
Tissue or Fluid	Dose/ Route	Patients	Postdose	mcg/g)
Urine	500 mg IM	6	0-2 h	2,100.0
	2 g IV	6	0-2 h	12,000.0
Bile	2 g IV	3	90 min	36.4
Synovial fluid	2 g IV	13	2 h	25.6
Peritoneal fluid	2 g IV	8	2 h	48.6
Sputum	1 g IV	8	1 h	9.0
Cerebrospinal fluid	2 g q8h IV	5	120 min	9.8
(inflamed meninges)	2 g q8h IV	6	180 min	9.4
Aqueous humor	2 g IV	13	1-3 h	11.0
Blister fluid	1 g IV	7	2-3 h	19.7
Lymphatic fluid	1 g IV	7	2-3 h	23.4
Bone	2 g IV	8	0.67 h	31.1
Heart muscle	2 g IV	35	30-280 min	12.7
Skin	2 g IV	22	30-180 min	6.6
Skeletal muscle	2 g IV	35	30-280 min	9.4
Myometrium	2 g IV	31	1-2 h	18.7

64

Microbiology: Ceftazidime is bactericidal in action, exerting its effect by inhibition of enzymes responsible for cell-wall synthesis. A wide range of gram-negative organisms is susceptible to ceftazidime *in vitro*, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins.

72 Ceftazidime has been shown to be active against the following organisms both *in vitro* and in

73 clinical infections (see INDICATIONS AND USAGE).

- 74 *Aerobes, Gram-negative: Citrobacter* spp., including *Citrobacter freundii* and *Citrobacter*
- 75 *diversus*; *Enterobacter* spp., including *Enterobacter cloacae* and *Enterobacter aerogenes*;
- 76 *Escherichia coli*; *Haemophilus influenzae*, including ampicillin-resistant strains; *Klebsiella* spp.
- 77 (including Klebsiella pneumoniae); Neisseria meningitidis; Proteus mirabilis; Proteus vulgaris;

78 Pseudomonas spp. (including Pseudomonas aeruginosa); and Serratia spp.

79 Aerobes, Gram-positive: Staphylococcus aureus, including penicillinase- and non-

80 penicillinase-producing strains; Streptococcus agalactiae (group B streptococcus); Streptococcus

81 *pneumoniae*; and *Streptococcus pyogenes* (group A beta-hemolytic streptococci).

82 *Anaerobes: Bacteroides* spp. (NOTE: many strains of *Bacteroides fragilis* are resistant).

83 Ceftazidime has been shown to be active *in vitro* against most strains of the following

84 organisms; however, the clinical significance of this activity is unknown: Acinetobacter spp.,

85 Clostridium spp. (not including Clostridium difficile), Haemophilus parainfluenzae, Morganella

86 morganii (formerly Proteus morganii), Neisseria gonorrhoeae, Peptococcus spp.,

87 Peptostreptococcus spp., Providencia spp. (including Providencia rettgeri, formerly Proteus

88 rettgeri), Salmonella spp., Shigella spp., Staphylococcus epidermidis, and Yersinia

89 enterocolitica.

90 Ceftazidime and the aminoglycosides have been shown to be synergistic *in vitro* against

91 *Pseudomonas aeruginosa* and the enterobacteriaceae. Ceftazidime and carbenicillin have also

92 been shown to be synergistic *in vitro* against *Pseudomonas aeruginosa*.

93 Ceftazidime is not active *in vitro* against methicillin-resistant staphylococci, *Streptococcus*

94 faecalis and many other enterococci, Listeria monocytogenes, Campylobacter spp., or

95 *Clostridium difficile.*

96 Susceptibility Tests: *Diffusion Techniques:* Quantitative methods that require measurement of

97 zone diameters give an estimate of antibiotic susceptibility. One such procedure¹⁻³ has been

98 recommended for use with disks to test susceptibility to ceftazidime.

Reports from the laboratory giving results of the standard single-disk susceptibility test with a
30-mcg ceftazidime disk should be interpreted according to the following criteria:

101 Susceptible organisms produce zones of 18 mm or greater, indicating that the test organism 102 is likely to respond to therapy.

103 Organisms that produce zones of 15 to 17 mm are expected to be susceptible if high dosage 104 is used or if the infection is confined to tissues and fluids (e.g., urine) in which high antibiotic 105 levels are attained.

106 Resistant organisms produce zones of 14 mm or less, indicating that other therapy should be107 selected.

108 Organisms should be tested with the ceftazidime disk since ceftazidime has been shown by *in*

109 *vitro* tests to be active against certain strains found resistant when other beta-lactam disks are

110 used.

111 Standardized procedures require the use of laboratory control organisms. The 30-mcg

112 ceftazidime disk should give zone diameters between 25 and 32 mm for *Escherichia coli*

113 ATCC 25922. For *Pseudomonas aeruginosa* ATCC 27853, the zone diameters should be

between 22 and 29 mm. For *Staphylococcus aureus* ATCC 25923, the zone diameters should be

115 between 16 and 20 mm.

116 Dilution Techniques: In other susceptibility testing procedures, e.g., ICS agar dilution or the 117 equivalent, a bacterial isolate may be considered susceptible if the minimum inhibitory

118 concentration (MIC) value for ceftazidime is not more than 16 mcg/mL. Organisms are

119 considered resistant to ceftazidime if the MIC is ≥64 mcg/mL. Organisms having an MIC value

120 of <64 mcg/mL but >16 mcg/mL are expected to be susceptible if high dosage is used or if the

121 infection is confined to tissues and fluids (e.g., urine) in which high antibiotic levels are attained.

122 As with standard diffusion methods, dilution procedures require the use of laboratory control

123 organisms. Standard ceftazidime powder should give MIC values in the range of 4 to 16 mcg/mL

124 for *Staphylococcus aureus* ATCC 25923. For *Escherichia coli* ATCC 25922, the MIC range

should be between 0.125 and 0.5 mcg/mL. For *Pseudomonas aeruginosa* ATCC 27853, the MIC

- range should be between 0.5 and 2 mcg/mL.
- 127

128 **INDICATIONS AND USAGE:** CEPTAZ is indicated for the treatment of patients with

129 infections caused by susceptible strains of the designated organisms in the following diseases:

130 **1. Lower Respiratory Tract Infections**, including pneumonia, caused by *Pseudomonas*

- 131 *aeruginosa* and other *Pseudomonas* spp.; *Haemophilus influenzae*, including
- 132 ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia

- 133 *coli*; *Serratia* spp.; *Citrobacter* spp.; *Streptococcus pneumoniae*; and *Staphylococcus aureus*
- 134 (methicillin-susceptible strains).
- 135 2. Skin and Skin-Structure Infections caused by *Pseudomonas aeruginosa*; *Klebsiella* spp.;
- 136 *Escherichia coli*; *Proteus* spp., including *Proteus mirabilis* and indole-positive *Proteus*;
- 137 Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and
- 138 *Streptococcus pyogenes* (group A beta-hemolytic streptococci).
- **3.** Urinary Tract Infections, both complicated and uncomplicated, caused by *Pseudomonas*
- 140 *aeruginosa; Enterobacter* spp.; *Proteus* spp., including *Proteus mirabilis* and indole-positive
- 141 *Proteus*; *Klebsiella* spp.; and *Escherichia coli*.
- 142 **4. Bacterial Septicemia** caused by *Pseudomonas aeruginosa*, *Klebsiella* spp., *Haemophilus*
- 143 *influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus*
- 144 *aureus* (methicillin-susceptible strains).
- **5. Bone and Joint Infections** caused by *Pseudomonas aeruginosa, Klebsiella* spp., *Enterobacter*spp., and *Staphylococcus aureus* (methicillin-susceptible strains).
- 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the
 female genital tract caused by *Escherichia coli*.
- 149 7. Intra-abdominal Infections, including peritonitis caused by *Escherichia coli*, *Klebsiella* spp.,
- and *Staphylococcus aureus* (methicillin-susceptible strains) and polymicrobial infections
- 151 caused by aerobic and anaerobic organisms and *Bacteroides* spp. (many strains of *Bacteroides* 152 *fragilis* are resistant).
- 153 8. Central Nervous System Infections, including meningitis, caused by *Haemophilus influenzae*
- and *Neisseria meningitidis*. Ceftazidime has also been used successfully in a limited number of
- 155 cases of meningitis due to *Pseudomonas aeruginosa* and *Streptococcus pneumoniae*.
- 156 Specimens for bacterial cultures should be obtained before therapy in order to isolate and
- 157 identify causative organisms and to determine their susceptibility to ceftazidime. Therapy may be
- 158 instituted before results of susceptibility studies are known; however, once these results become
- 159 available, the antibiotic treatment should be adjusted accordingly.
- 160 CEPTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been
- 161 used successfully in clinical trials as empiric therapy in cases where various concomitant
- 162 therapies with other antibiotics have been used.

163	CEPTAZ may also be used concomitantly with other antibiotics, such as aminoglycosides,
164	vancomycin, and clindamycin; in severe and life-threatening infections; and in the
165	immunocompromised patient (see COMPATIBILITY AND STABILITY). When such
166	concomitant treatment is appropriate, prescribing information in the labeling for the other
167	antibiotics should be followed. The dosage depends on the severity of the infection and the
168	patient's condition.
169	
170	CONTRAINDICATIONS: CEPTAZ is contraindicated in patients who have shown
171	hypersensitivity to ceftazidime or the cephalosporin group of antibiotics.
172	
173	WARNINGS: BEFORE THERAPY WITH CEPTAZ IS INSTITUTED, CAREFUL INQUIRY
174	SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS
175	HYPERSENSITIVITY REACTIONS TO CEFTAZIDIME, CEPHALOSPORINS,
176	PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO
177	PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE
178	CROSS-HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN
179	CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A
180	HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEPTAZ
181	OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY
182	REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER
183	EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES,
184	CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS
185	CLINICALLY INDICATED.
186	Pseudomembranous colitis has been reported with nearly all antibacterial agents,
187	including ceftazidime, and may range in severity from mild to life threatening. Therefore, it
188	is important to consider this diagnosis in patients who present with diarrhea subsequent to
189	the administration of antibacterial agents.
190	Treatment with antibacterial agents alters the normal flora of the colon and may permit
191	overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is one
192	primary cause of "antibiotic-associated colitis."

After the diagnosis of pseudomembranous colitis has been established, appropriate therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against *Clostridium difficile* colitis.

198 Elevated levels of ceftazidime in patients with renal insufficiency can lead to seizures,

199 encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia (see

200 PRECAUTIONS).

201

202 **PRECAUTIONS:**

203 General: High and prolonged serum ceftazidime concentrations can occur from usual dosages in

204 patients with transient or persistent reduction of urinary output because of renal insufficiency.

205 The total daily dosage should be reduced when ceftazidime is administered to patients with renal

206 insufficiency (see DOSAGE AND ADMINISTRATION). Elevated levels of ceftazidime in these

207 patients can lead to seizures, encephalopathy, coma, asterixis, neuromuscular excitability, and

208 myoclonia. Continued dosage should be determined by degree of renal impairment, severity of

209 infection, and susceptibility of the causative organisms.

As with other antibiotics, prolonged use of CEPTAZ may result in overgrowth of

211 nonsusceptible organisms. Repeated evaluation of the patient's condition is essential. If

superinfection occurs during therapy, appropriate measures should be taken.

213 Inducible type I beta-lactamase resistance has been noted with some organisms (e.g.,

214 Enterobacter spp., Pseudomonas spp., and Serratia spp.). As with other extended-spectrum

215 beta-lactam antibiotics, resistance can develop during therapy, leading to clinical failure in some

216 cases. When treating infections caused by these organisms, periodic susceptibility testing should

217 be performed when clinically appropriate. If patients fail to respond to monotherapy, an

aminoglycoside or similar agent should be considered.

Cephalosporins may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy. Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated.

CEPTAZ should be prescribed with caution in individuals with a history of gastrointestinal
 disease, particularly colitis.

Arginine has been shown to alter glucose metabolism and elevate serum potassium transiently when administered at 50 times the recommended dose. The effect of lower dosing is not known.

227 Distal necrosis can occur after inadvertent intra-arterial administration of ceftazidime.

228 Drug Interactions: Nephrotoxicity has been reported following concomitant administration of

229 cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide. Renal

230 function should be carefully monitored, especially if higher dosages of the aminoglycosides are to

be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity

of aminoglycosidic antibiotics. Nephrotoxicity and ototoxicity were not noted when ceftazidime

233 was given alone in clinical trials.

234 Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including

235 ceftazidime, based on *in vitro* studies and time kill curves with enteric gram-negative bacilli. Due

to the possibility of antagonism *in vivo*, particularly when bactericidal activity is desired, this

237 drug combination should be avoided.

238 **Drug/Laboratory Test Interactions:** The administration of ceftazidime may result in a

239 false-positive reaction for glucose in the urine when using CLINITEST[®] tablets, Benedict's

solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose

241 oxidase reactions (such as CLINISTIX[®]) be used.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals have not
been performed to evaluate carcinogenic potential. However, a mouse Micronucleus test and an
Ames test were both negative for mutagenic effects.

Pregnancy: *Teratogenic Effects:* Pregnancy Category B. Reproduction studies have been performed in mice and rats at doses up to 40 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to ceftazidime. CEPTAZ at 23 times the human dose was not teratogenic or embryotoxic in a rat reproduction study. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

252 Nursing Mothers: Ceftazidime is excreted in human milk in low concentrations. It is not known

- whether the arginine component of this product is excreted in human milk. Because many drugs are excreted in human milk and because safety of the arginine component of CEPTAZ in nursing infants has not been established, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
- 257 **Pediatric Use:** Safety of the arginine component of CEPTAZ in neonates, infants, and children
- has not been established. This product is for use in patients 12 years and older. If treatment with
 ceftazidime is indicated for neonates, infants, or children, a sodium carbonate formulation should
- be used.
- 261

262 ADVERSE REACTIONS: The following adverse effects from clinical trials were considered to

263 be either related to ceftazidime therapy or were of uncertain etiology. The most common were

264 local reactions following IV injection and allergic and gastrointestinal reactions. No

- 265 disulfiramlike reactions were reported.
- Local Effects, reported in fewer than 2% of patients, were phlebitis and inflammation at the siteof injection (1 in 69 patients).

268 Hypersensitivity Reactions, reported in 2% of patients, were pruritus, rash, and fever.

269 Immediate reactions, generally manifested by rash and/or pruritus, occurred in 1 in 285 patients.

270 Toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have also been

271 reported with cephalosporin antibiotics, including ceftazidime. Angioedema and anaphylaxis

272 (bronchospasm and/or hypotension) have been reported very rarely.

273 Gastrointestinal Symptoms, reported in fewer than 2% of patients, were diarrhea (1 in 78),

nausea (1 in 156), vomiting (1 in 500), and abdominal pain (1 in 416). The onset of

275 pseudomembranous colitis symptoms may occur during or after treatment (see WARNINGS).

276 Central Nervous System Reactions (fewer than 1%) included headache, dizziness, and

277 paresthesia. Seizures have been reported with several cephalosporins, including ceftazidime. In

addition, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been

279 reported in renally impaired patients treated with unadjusted dosage regimens of ceftazidime (see

280 PRECAUTIONS: General).

Less Frequent Adverse Events (fewer than 1%) were candidiasis (including oral thrush) and
vaginitis.

- 283 Hematologic: Rare cases of hemolytic anemia have been reported.
- 284 Laboratory Test Changes noted during ceftazidime clinical trials were transient and included:
- eosinophilia (1 in 13), positive Coombs' test without hemolysis (1 in 23), thrombocytosis (1 in
- 45), and slight elevations in one or more of the hepatic enzymes, aspartate aminotransferase
- 287 (AST, SGOT) (1 in 16), alanine aminotransferase (ALT, SGPT) (1 in 15), LDH (1 in 18), GGT (1
- in 19), and alkaline phosphatase (1 in 23). As with some other cephalosporins, transient
- 289 elevations of blood urea, blood urea nitrogen, and/or serum creatinine were observed
- 290 occasionally. Transient leukopenia, neutropenia, agranulocytosis, thrombocytopenia, and
- 291 lymphocytosis were seen very rarely.
- 292

293 **POSTMARKETING EXPERIENCE WITH CEPTAZ PRODUCTS:** In addition to the

- adverse events reported during clinical trials, the following events have been observed during
- 295 clinical practice in patients treated with CEPTAZ and were reported spontaneously. For some of
- these events, data are insufficient to allow an estimate of incidence or to establish causation.
- 297 General: Anaphylaxis; allergic reactions, which, in rare instances, were severe (e.g.,
- 298 cardiopulmonary arrest); urticaria; pain at injection site.
- 299 Hepatobiliary Tract: Hyperbilirubinemia, jaundice.
- 300 Renal and Genitourinary: Renal impairment.
- 301 Cephalosporin-Class Adverse Reactions: In addition to the adverse reactions listed above that
- 302 have been observed in patients treated with ceftazidime, the following adverse reactions and
- 303 altered laboratory tests have been reported for cephalosporin-class antibiotics:
- 304 *Adverse Reactions:* Colitis, toxic nephropathy, hepatic dysfunction including cholestasis,
 305 aplastic anemia, hemorrhage.
- 306 *Altered Laboratory Tests:* Prolonged prothrombin time, false-positive test for urinary
 307 glucose, pancytopenia.
- 308
- 309 **OVERDOSAGE:** Ceftazidime overdosage has occurred in patients with renal failure. Reactions
- 310 have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.
- 311 Patients who receive an acute overdosage should be carefully observed and given supportive
- 312 treatment. In the presence of renal insufficiency, hemodialysis or peritoneal dialysis may aid in

- 313 the removal of ceftazidime from the body.
- 314

315 DOSAGE AND ADMINISTRATION:

- 316 **Dosage:** The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8
- to 12 hours. The dosage and route should be determined by the susceptibility of the causative
- 318 organisms, the severity of infection, and the condition and renal function of the patient.
- 319 The guidelines for dosage of CEPTAZ are listed in Table 3. The following dosage schedule is
- 320 recommended.

Table 3: Recommended Dosage Schedule

	Dose	Frequency
Patients 12 years and older*		
Usual recommended dosage	1 gram IV or IM	q8-12h
Uncomplicated urinary tract infections	250 mg IV or IM	q12h
Bone and joint infections	2 grams IV	q12h
Complicated urinary tract infections	500 mg IV or IM	q8-12h
Uncomplicated pneumonia; mild skin and skin-	500 mg-1 gram	
structure infections	IV or IM	q8h
Serious gynecologic and intra-abdominal infections	2 grams IV	q8h
Meningitis	2 grams IV	q8h
Very severe life-threatening infections, especially		
in immunocompromised patients	2 grams IV	q8h
Lung infections caused by Pseudomonas spp. in	30-50 mg/kg IV	
patients with cystic fibrosis with normal renal	to a maximum	
function ^{\dagger}	of 6 grams per day	q8h
This product is for use in patients 12 years and older.	If treatment with ceftaz	zidime is
indicated for patients less than 12 years old, a sodium	carbonate formulation	should
be used.		
Although clinical improvement has been shown, bacted	eriologic cures cannot l	be
expected in patients with chronic respiratory disease a	nd cystic fibrosis.	

328

323

324

325

326

327

Impaired Hepatic Function: No adjustment in dosage is required for patients with hepaticdysfunction.

331 *Impaired Renal Function:* Ceftazidime is excreted by the kidneys, almost exclusively by

332 glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration

- rate [GFR]<50 mL/min), it is recommended that the dosage of ceftazidime be reduced to
- 334 compensate for its slower excretion. In patients with suspected renal insufficiency, an initial
- loading dose of 1 gram of CEPTAZ may be given. An estimate of GFR should be made to
- determine the appropriate maintenance dosage. The recommended dosage is presented in Table 4.

- 337
- 338 Table 4: Recommended Maintenance Dosages of CEPTAZ in Renal Insufficiency
- 339 NOTE: IF THE DOSE RECOMMENDED IN TABLE 3 ABOVE IS LOWER THAN
- 340 THAT RECOMMENDED FOR PATIENTS WITH RENAL INSUFFICIENCY AS

341 OUTLINED IN TABLE 4, THE LOWER DOSE SHOULD BE USED.

Creatinine Clearance	Recommended Unit Dose		
(mL/min)	of CEPTAZ	Frequency of Dosing	
50-31	1 gram	q12h	
30-16	1 gram	q24h	
15-6	500 mg	q24h	
<5	500 mg	q48h	

³⁴²

343	When only serum creatinine is available, the following formula (Cockcroft's equation) ⁴ may be
344	used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal
345	function:
346	
347	Males: Creatinine clearance (mL/min) = <u>Weight (kg) x (140 - age)</u>
348	72 x serum creatinine (mg/dL)
349	Females: 0.85 x male value
350	
351	In patients with severe infections who would normally receive 6 grams of CEPTAZ daily were
352	it not for renal insufficiency, the unit dose given in the table above may be increased by 50% or
353	the dosing frequency may be increased appropriately. Further dosing should be determined by
354	therapeutic monitoring, severity of the infection, and susceptibility of the causative organism.
355	In patients undergoing hemodialysis, a loading dose of 1 gram is recommended, followed by
356	1 gram after each hemodialysis period.
357	CEPTAZ can also be used in patients undergoing intraperitoneal dialysis and continuous
358	ambulatory peritoneal dialysis. In such patients, a loading dose of 1 gram of CEPTAZ may be
359	given, followed by 500 mg every 24 hours. It is not known whether or not CEPTAZ can be safely
360	incorporated into dialysis fluid.

361 **Note:** Generally CEPTAZ should be continued for 2 days after the signs and symptoms of

362 infection have disappeared, but in complicated infections longer therapy may be required.

363 Administration: CEPTAZ may be given intravenously or by deep IM injection into a large

364 muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh.

365 Intra-arterial administration should be avoided (see PRECAUTIONS).

366 *Intramuscular Administration:* For IM administration, CEPTAZ should be constituted with

367 one of the following diluents: Sterile Water for Injection, Bacteriostatic Water for Injection, or

368 0.5% or 1% Lidocaine Hydrochloride Injection. Refer to Table 5.

369 *Intravenous Administration:* The IV route is preferable for patients with bacterial septicemia, 370 bacterial meningitis, peritonitis, or other severe or life-threatening infections, or for patients who 371 may be poor risks because of lowered resistance resulting from such debilitating conditions as 372 malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is 373 present or pending.

For direct intermittent IV administration, constitute CEPTAZ as directed in Table 5 with
Sterile Water for Injection, 5% Dextrose Injection, or 0.9% Sodium Chloride Injection. Slowly
inject directly into the vein over a period of 3 to 5 minutes or give through the tubing of an
administration set while the patient is also receiving one of the compatible IV fluids (see
COMPATIBILITY AND STABILITY).

For IV infusion, constitute the 1- or 2-gram infusion pack with 100 mL of Sterile Water for
 Injection or one of the compatible IV fluids listed under the COMPATIBILITY AND
 STABILITY section. Alternatively, constitute the 1- or 2-gram vial and add an appropriate
 quantity of the resulting solution to an IV container with one of the compatible IV fluids.
 Intermittent IV infusion with a Y-type administration set can be accomplished with

compatible solutions. However, during infusion of a solution containing ceftazidime, it isdesirable to discontinue the other solution.

			Approximate
			Ceftazidime
	Amount of Diluent	Volume to Be	Concentration
Size	to Be Added (mL)	Withdrawn (mL)	(mg/mL)
Intramuscular			
1-gram vial	3.0	Total	250
Intravenous			
1-gram vial	10.0	Total	90
2-gram vial	10.0	Total	170
Infusion pack			
1-gram vial	100		10
2-gram vial	100		20
Pharmacy bulk package			
10-gram vial	40	Amount needed	200

Table 5: Preparation of Solutions of CEPTAZ

388

389 Solutions of CEPTAZ, like those of most beta-lactam antibiotics, should not be added to
390 solutions of aminoglycoside antibiotics because of potential interaction.

However, if concurrent therapy with CEPTAZ and an aminoglycoside is indicated, each ofthese antibiotics can be administered separately to the same patient.

Instructions for Constitution: Vials of CEPTAZ as supplied are under a slightly reduced pressure. This may assist entry of the diluent. No gas-relief needle is required when adding the diluent, except for the infusion pack where it is required during the latter stages of addition (in order to preserve product sterility, a gas-relief needle should not be inserted until an overpressure is produced in the vial). No evolution of gas occurs on constitution. When the vial contents are dissolved, vials other than infusion packs may still be under a reduced pressure. This reduced pressure is particularly noticeable for the 10-gram pharmacy bulk package.

400

401 **COMPATIBILITY AND STABILITY:**

402 Intramuscular: CEPTAZ, when constituted as directed with Sterile Water for Injection,

403 Bacteriostatic Water for Injection, or 0.5% or 1% Lidocaine Hydrochloride Injection, maintains 404 satisfactory potency for 18 hours at room temperature or for 7 days under refrigeration. Solutions 405 in Sterile Water for Injection that are frozen immediately after constitution in the original 406 container are stable for 6 months when stored at -20°C. Components of the solution may 407 precipitate in the frozen state and will dissolve on reaching room temperature with little or no 408 agitation. Potency is not affected. Frozen solutions should only be thawed at room temperature. 409 Do not force thaw by immersion in water baths or by microwave irradiation. Once thawed, 410 solutions should not be refrozen. Thawed solutions may be stored for up to 12 hours at room 411 temperature or for 7 days in a refrigerator.

412 Intravenous: Ceftazidime concentration greater than 100 mg/mL (2-g vial or 10-g pharmacy

413 bulk package): CEPTAZ, when constituted as directed with Sterile Water for Injection, 0.9% 414 Sodium Chloride Injection, or 5% Dextrose Injection, maintains satisfactory potency for 18 hours 415 at room temperature or for 7 days under refrigeration. Solutions of a similar concentration in 416 Sterile Water for Injection that are frozen immediately after constitution in the original container 417 are stable for 6 months when stored at -20°C. Components of the solution may precipitate in the 418 frozen state and will dissolve upon reaching room temperature with little or no agitation. Potency 419 is not affected. Frozen solutions should only be thawed at room temperature. Do not force thaw 420 by immersion in water baths or by microwave irradiation. Once thawed, solutions should not be 421 refrozen. Thawed solutions may be stored for up to 12 hours at room temperature or for 7 days in 422 a refrigerator.

423 *Ceftazidime concentration of 100 mg/mL or less (1-g vial or infusion packs):* CEPTAZ,

424 when constituted as directed with Sterile Water for Injection, 0.9% Sodium Chloride Injection, or

425 5% Dextrose Injection, maintains satisfactory potency for 24 hours at room temperature or for

426 7 days under refrigeration. Solutions, prepared by a pharmacist, of the approved arginine

427 formulation of ceftazidime of a similar concentration in Sterile Water for Injection, 0.9% Sodium

428 Chloride Injection, or 5% Dextrose Injection in the original container or in 0.9% Sodium

429 Chloride Injection in VIAFLEX[®] (PL 146[®] Plastic) small-volume containers that are frozen

430 immediately after constitution by the pharmacist are stable for 6 months when stored at -20°C.

431 Solutions in the PL 146 Plastic small-volume containers are in contact with the polyvinyl chloride

432 layer of this container and can leach out certain chemical components of the plastic in very small

433 amounts within the expiration period. The suitability of the plastic has been confirmed in tests in 434 animals according to USP biological tests for plastic containers as well as by tissue culture 435 toxicity studies. Stability of the frozen solution in other containers has not been confirmed. 436 Frozen solutions should only be thawed at room temperature. Do not force thaw by immersion in 437 water baths or by microwave irradiation. For the larger volumes of IV infusion solutions where it 438 may be necessary to warm the frozen product, care should be taken to avoid heating after thawing 439 is complete. Once thawed, solutions should not be refrozen. Thawed solutions may be stored for 440 up to 18 hours at room temperature or for 7 days in a refrigerator.

441 Components of the solution may precipitate in the frozen state and will dissolve on reaching 442 room temperature with little or no agitation. Potency is not affected. Check for minute leaks in 443 plastic containers by squeezing bag firmly. Discard bag if leaks are found as sterility may be 444 impaired. Do not add supplementary medication to bags. Do not use unless solution is clear and 445 seal is intact.

446 Use sterile equipment.

447 *Caution:* Do not use plastic containers in series connections. Such use could result in air

448 embolism due to residual air being drawn from the primary container before administration of the

449 fluid from the secondary container is complete.

450 *Preparation for Administration:*

451 1. Suspend container from eyelet support.

452 2. Remove protector from outlet port at bottom of container.

453 3. Attach administration set. Refer to complete directions accompanying set.

454 CEPTAZ is compatible with the more commonly used IV infusion fluids. Solutions at

455 concentrations between 1 and 40 mg/mL in 0.9% Sodium Chloride Injection; 1/6 M Sodium

456 Lactate Injection; 5% Dextrose Injection; 5% Dextrose and 0.225% Sodium Chloride Injection;

457 5% Dextrose and 0.45% Sodium Chloride Injection; 5% Dextrose and 0.9% Sodium Chloride

458 Injection; 10% Dextrose Injection; Ringer's Injection, USP; Lactated Ringer's Injection, USP;

459 10% Invert Sugar in Sterile Water for Injection; and Normosol[®]-M in 5% Dextrose Injection may

460 be stored for up to 24 hours at room temperature or for 7 days if refrigerated.

461 CEPTAZ is less stable in Sodium Bicarbonate Injection than in other IV fluids. It is not

462 recommended as a diluent. Solutions of CEPTAZ in 5% Dextrose Injection and 0.9% Sodium

463 Chloride Injection are stable for at least 6 hours at room temperature in plastic tubing, drip464 chambers, and volume control devices of common IV infusion sets.

465 Ceftazidime at a concentration of 4 mg/mL has been found compatible for 24 hours at room

temperature or for 7 days under refrigeration in 0.9% Sodium Chloride Injection or 5% Dextrose

467 Injection when admixed with: cefuroxime sodium (ZINACEF[®]) 3 mg/mL; heparin sodium in

468 concentrations up to 50 U/mL; or potassium chloride in concentrations up to 40 mEq/L.

469 Ceftazidime may be constituted at a concentration of 20 mg/mL with metronidazole injection

 $470 \quad 5 \text{ mg/mL}$, and the resultant solution may be stored for 24 hours at room temperature or for 7 days

471 under refrigeration. Ceftazidime at a concentration of 20 mg/mL has been found compatible for

472 24 hours at room temperature or for 7 days under refrigeration in 0.9% Sodium Chloride Injection

473 or 5% Dextrose Injection when admixed with 6 mg/mL clindamycin (as clindamycin phosphate).

474 Vancomycin solution exhibits a physical incompatibility when mixed with a number of drugs,

475 including ceftazidime. The likelihood of precipitation with ceftazidime is dependent on the

476 concentrations of vancomycin and ceftazidime present. It is therefore recommended, when both

477 drugs are to be administered by intermittent IV infusion, that they be given separately, flushing

478 the IV lines (with one of the compatible IV fluids) between the administration of these two

479 agents.

480 **Note:** Parenteral drug products should be inspected visually for particulate matter before

481 administration whenever solution and container permit.

As with other cephalosporins, CEPTAZ powder as well as solutions tend to darken, depending
on storage conditions; within the stated recommendations, however, product potency is not
adversely affected.

485 **Directions for Dispensing:** *Pharmacy Bulk Package—Not for Direct Infusion:* The pharmacy 486 bulk package is for use in a pharmacy admixture service only under a laminar flow hood. Entry 487 into the vial must be made with a sterile transfer set or other sterile dispensing device, and the 488 contents dispensed in aliquots using aseptic technique. The use of syringe and needle is not 489 recommended as it may cause leakage (see DOSAGE AND ADMINISTRATION). GOOD 490 PHARMACY PRACTICE DICTATES THAT THE CLOSURE BE PENETRATED ONLY 491 ONE TIME AFTER CONSTITUTION. AFTER INITIAL PENETRATION OF THE CLOSURE, 492 USE ENTIRE CONTENTS OF VIAL PROMPTLY. ANY UNUSED PORTION MUST BE

493 DISCARDED WITHIN 18 HOURS OF CONSTITUTION.

494

- 495 **HOW SUPPLIED:** CEPTAZ in the dry state should be stored between 15° and 30°C (59° and
- 496 86°F) and protected from light. CEPTAZ is a dry, white to off-white powder supplied in vials and
- 497 infusion packs as follows:
- 498 NDC 0173-0414-00 1-g* Vial (Tray of 25)
- 499 NDC 0173-0415-00 2-g* Vial (Tray of 25)
- 500 NDC 0173-0416-00 1-g* Infusion Pack (Tray of 10)
- 501 NDC 0173-0417-00 2-g* Infusion Pack (Tray of 10)
- 502 NDC 0173-0418-00 10-g* Pharmacy Bulk Package (Tray of 6)
- 503 *Equivalent to anhydrous ceftazidime.
- 504

505 **REFERENCES:**

- Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a
 standardized single disk method. *Am J Clin Pathol*. 1966;45:493-496.
- National Committee for Clinical Laboratory Standards. *Approved Standard: Performance Standards for Antimicrobial Disc Susceptibility Tests*. (M2-A3). December 1984.
- 510 3. Certification procedure for antibiotic sensitivity discs (21 CFR 460.1). *Federal Register*. May
- 511 30, 1974;39:19182-19184.
- 512 4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine.
- 513 *Nephron*. 1976;16:31-41.
- 514
- 515



- 517 GlaxoSmithKline
- 518 Research Triangle Park, NC 27709
- 519 Made in England
- 520
- 521 CEPTAZ and ZINACEF are registered trademarks of GlaxoSmithKline.

- 522 CLINITEST and CLINISTIX are registered trademarks of Ames Division, Miles Laboratories,
- 523 Inc.
- 524 VIAFLEX and PL 146 Plastic are registered trademarks of Baxter International Inc.
- 525
- 526
- 527 Date of Issue RL-
- 528

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Janice Soreth 3/29/02 04:18:27 PM